In this interview, Spencer King and Marc Bonaca discuss insights from the DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58) trial, specifically dapagliflozin and outcomes in patients with peripheral artery disease.

In this interview, Deepak Bhatt and Holly Middlekauff discuss what every cardiologist needs to know about vaping.

In this interview, Robert Schwartz and Michael Reardon discuss the Evolut Low Risk trial (Self-Expanding Transcatheter or Surgical Aortic Valve Replacement in Patients at Low Risk of Surgical Mortality).

In this interview, Peter McCullough and Matthew Budoff discuss the association of coronary artery calcification with subsequent cardiovascular disease in DCCT (Diabetes Control and Complications Trial) and the EDIC (Epidemiology of Diabetes Interventions and Complications) study.

In this interview, David Moliterno and Setri Fugar discuss Outcomes of Transcatheter and Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis and Pulmonary Hypertension: A Nationwide Inpatient Sample Matched Analysis.

In this interview, Freek Verheugt and Colin Berry discuss T-TIME, a randomized, double blind, placebo-controlled, parallel group, multicenter clinical trial of low-dose adjunctive alteplase during primary percutaneous coronary intervention.

In this interview, Spencer King and David Wilbur discuss atrial fibrillation, catheter ablation, and the results of the CABANA trial (Catheter Ablation vs Antiarrhythmic Drug Therapy in Atrial Fibrillation).

In this interview, Gerald V. Naccarelli and Stephen D. Wiviott discuss the DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58) trial.

In this interview, Stephen J. Nicholls and Sotirios Tsimikas discuss AKCEA: Safety and Efficacy of AKCEA-APO(a)-to Lower Lipoprotein(a) Levels in Patients with Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial.

In this interview, Noel Bairey Merz and Ron Waksman discuss LRP: Assessment of Coronary Near-Infrared Spectroscopy Imaging to Detect Vulnerable Plaques and Vulnerable Patients.